Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 870

Sort by

Sort Order Select

Journal Articles

The different flavors and splices of MCL

Oliver Weigert

Blood (2020) 136 (5): 526–527.

https://doi.org/10.1182/blood.2020005591

Published: 2020

Journal Articles

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

Blood (2020) 135 (6): 411–428.

https://doi.org/10.1182/blood.2019001262

Published: 2020

Includes: Supplemental data

Journal Articles

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

McKensie Collins, BS, Weimin Kong, PhD, Inyoung Jung, BS, Meng Wang, BS, Stefan M Lundh, BS, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 681.

https://doi.org/10.1182/blood-2019-122063

Published: 2019

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Superoxide Drives PI3 Kinase Mediated Mitochondria Transfer from the Bone Marrow Microenvironment to Hematopoietic Stem Cells in Response to Salmonella Typhimurium

Jayna J Mistry, BSc, Christopher R Marlein, PhD, Jamie A Moore, BSc, MSc, Charlotte Hellmich, MBBChir, Iain Macauley, PhD BSc, Naiara Beraza, PhD, Yu Sun, BSc, MSc, PhD, Adam Morfakis, BSc, Angela Patterson, PhD, Rebecca H Horton, Devina Divekar, Christopher J Morris, PhD, Anna Haestier, Bsc, PgD MBBS, MRCOG, Federica Di Palma, PhD, Kristian M Bowles, MBBS, PhD, Stuart A Rushworth, PhD

Blood (2019) 134 (Supplement_1): 2490.

https://doi.org/10.1182/blood-2019-128241

Published: 2019

Journal Articles

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

Shonali Midha, MD, Julio C. Chavez, MD, Hayder Saeed, MD, Celeste Bello, MD, Farhad Khimani, MD, Silvia Tse Bunting, MD MSc, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 5347.

https://doi.org/10.1182/blood-2019-130721

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Ann-Marie E Bröske, PhD, Ian James, PhD, Anton Belousov, PhD, Enrique Gomez, PhD, Marta Canamero, MD PhD, Chia-Huey Ooi, PhD, Nils Grabole, PhD, Sabine Wilson, PhD, Koorosh Korfi, PhD, Nicole A Kratochwil, PhD, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Denise Thomas, MSc, Natalie Dimier, PhD, Tom Moore, MBChB, Marina Bacac, PhD, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 5319.

https://doi.org/10.1182/blood-2019-123979

Published: 2019

Journal Articles

Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement

Zachary AK Frosch, MD, Sunita Dwivedy Nasta, MD, Stephen J. Schuster, MD, Jakub Svoboda, MD, Stefan K. Barta, MD MRCP, MS, James N. Gerson, MD, Elise A. Chong, MD, Emily C. Ayers, MD, Joanna M Rhodes, MD, Alexa Koike, Jennifer J.D. Morrissette, PhD, Daniel J. Landsburg, MD

Blood (2019) 134 (Supplement_1): 1607.

https://doi.org/10.1182/blood-2019-125944

Published: 2019

Journal Articles

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Blood (2019) 134 (Supplement_1): 3987.

https://doi.org/10.1182/blood-2019-126044

Published: 2019

Journal Articles

Codanin-1 Mutations Engineered in Human Erythroid Cells Allow Investigation of Mechanisms Underlying Congenital Dyserythropoietic Anemia

Zachary C. Murphy, PhD, Michael Getman, MS, Jacquelyn Lillis, Laurie A. Steiner, MD

Blood (2019) 134 (Supplement_1): 3739.

https://doi.org/10.1182/blood-2019-127415

Published: 2019

Journal Articles

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

Nikesh Shah, MD, Franco Castillo-Tokumori, MD, Julio C. Chavez, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Lubomir Sokol, MD PhD, Javier Pinilla Ibarz, MD PhD, Bijal Shah, MD

Blood (2019) 134 (Supplement_1): 3991.

https://doi.org/10.1182/blood-2019-127291

Published: 2019

Journal Articles

R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma

Juan Pablo Alderuccio, MD, Sunil Iyer, MD, Isildinha M Reis, PhD, Alvaro J. Alencar, MD, Joseph D. Rosenblatt, MD, Izidore S. Lossos, MD

Blood (2019) 134 (Supplement_1): 3992.

https://doi.org/10.1182/blood-2019-125004

Published: 2019

Journal Articles

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Blood (2019) 134 (Supplement_1): 3993.

https://doi.org/10.1182/blood-2019-125947

Published: 2019

Journal Articles

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients in China in the Rituximab Era

Yun Li, MD PhD, Meng Wu, MD, Huiqiang Huang, MD PhD, Wei Xu, MD PhD, Haiwen Huang, MD PhD, Weili Zhao, MD PhD, Yanyan Wang, MD, Shuo Liu, MD, Pengpeng Xu, MD, Zhengming Chen, Yuqin Song, MD PhD, Jia Ruan, MD PhD, Depei Wu, MD PhD

Blood (2019) 134 (Supplement_1): 3994.

https://doi.org/10.1182/blood-2019-125192

Published: 2019

Journal Articles

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Hong Zheng, MD PhD, Shin Mineishi, David F. Claxton, MD, Junjia Zhu, Chenchen Zhao, MD, Bei Jia, MD PhD, W. Christopher Ehmann, MD, Seema Naik, MD, Natthapol Songdej, Raymond J. Hohl

Blood (2019) 134 (Supplement_1): 3939.

https://doi.org/10.1182/blood-2019-125153

Published: 2019

Journal Articles

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

Karolyn A. Oetjen, MD, Diane E. Bender, PhD, Marianna B. Ruzinova, MD PhD, Stephen T. Oh, MD, Daniel C. Link, MD

Blood (2019) 134 (Supplement_1): 3728.

https://doi.org/10.1182/blood-2019-127460

Published: 2019

Journal Articles

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

Martin Dreyling, MD, Eva Hoster, PhD, Michael Unterhalt, PhD, Andreas Rosenwald, MD, Hanneke Kluin-Nelemans, MD, Olivier Hermine, MD PhD, Wolfram Klapper

Blood (2019) 134 (Supplement_1): 3996.

https://doi.org/10.1182/blood-2019-130068

Published: 2019

Journal Articles

Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group

Charline Moulin, Romain Morizot, Thomas Remen, Hélène Augé, Florian Bouclet, Marion Divoux, Sandra Lomazzi, Caroline Dartigeas, MD, Anne Quinquenel, MD, Hélène Busby, MD, Cecile Tomowiak, Veronique Leblond, MD PhD, Catherine Thieblemont, MD PhD, Florence Cymbalista, MD PhD, Marie C Bene, PharmD,DPhil, Romain Guièze, MD PhD, Julien Broseus, MD PhD, Pierre Feugier, MD PhD

Blood (2019) 134 (Supplement_1): 4112.

https://doi.org/10.1182/blood-2019-128053

Published: 2019

Journal Articles

Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome

Nouf Alrasheed, Lydia Lee, Huw Richards, William Wilson, Oliver C Cohen, MBBS, BSc, FRCPath, Selina J Chavda, Jake Henry, Andrew Furness, Melody Chin, Daria Galas-Filipowicz, Charalampia Kyriakou, Neil K Rabin, Sergio A Quezada, Kwee Yong

Blood (2019) 134 (Supplement_1): 4368.

https://doi.org/10.1182/blood-2019-126682

Published: 2019

Journal Articles

Multiple Pathways Targeting CD25 or TNFRSF25 Affect CD4 + FoxP3 + Regulatory T Cell Phenotype and Suppressive Function

Sabrina N. Copsel, PhD, Henry Barreras, MPH, Casey O. Lightbourn, BS, MS, Cameron S. Bader, BS, Dietlinde Wolf, PhD, Brandon Kale, Warren Alperstein, MD, Krishna V Komanduri, MD, Robert B. Levy, PhD

Blood (2019) 134 (Supplement_1): 4430.

https://doi.org/10.1182/blood-2019-130649

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The different flavors and splices of MCL

Integrative analysis of spontaneous CLL regression highlights genetic and microenvironmental interdependency in CLL

A Failure to Start: Aborted Activation of CAR T Cells in Chronic Lymphocytic Leukemia

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Superoxide Drives PI3 Kinase Mediated Mitochondria Transfer from the Bone Marrow Microenvironment to Hematopoietic Stem Cells in Response to Salmonella Typhimurium

The Grey Zone: Characterization of Aggressive High-Grade B-Cell Malignancy with TdT Expression and IGH/BCL2 and MYC Rearrangement

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Induces T-Cell-Mediated Killing in Relapsed or Refractory Non-Hodgkin Lymphoma: Biomarker Results From a Phase I Dose-Escalation Trial

Outcomes for Double Hit Lymphoma Patients Identified Via Routine Vs Selective Testing for MYC Rearrangement

Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age ≤ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial

Codanin-1 Mutations Engineered in Human Erythroid Cells Allow Investigation of Mechanisms Underlying Congenital Dyserythropoietic Anemia

Use of Lenalidomide Plus Rituximab in TP53-Mutated Mantle Cell Lymphoma (MCL) Outside of Clinic Trial: The Moffitt Experience

R-MACLO-IVAM Is an Effective Regimen to Induce Long Term Remission in Untreated Mantle Cell Lymphoma

Ibrutinib at First Relapse for Mantle Cell Lymphoma: A United Kingdom Real World Analysis of Outcomes in 169 Patients

Initial Treatment Patterns and Survival Outcomes of Mantle Cell Lymphoma Patients in China in the Rituximab Era

Effect of Avelumab to Immune Response in AML: A Phase I Study of Avelumab in Combination with Decitabine As First Line Treatment of Unfit Patients

Interrogating the Spatial Architecture of Human Bone Marrow Via Imaging Mass Cytometry

Clinical Outcome of Mantle Cell Lymphoma Patients with High Risk Biology (high Ki-67, blastic MCL, or high p53 expression)

Clinical and Biological Characteristics and Outcomes of Richter Transformation : A French Multicenter Study from the Filo Group

Frequency of Marrow Infiltrating PD-1 Expressing CD4 Effectors Following Autologous Stem Cell Transplant (ASCT) for Multiple Myeloma Is Prognostic for Clinical Outcome

Multiple Pathways Targeting CD25 or TNFRSF25 Affect CD4 + FoxP3 + Regulatory T Cell Phenotype and Suppressive Function

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only